Charles C. Duncan

About

Person
Thing
Cofactor will automatically discover the description of this topic and display it here.

Mentions

An approval will de-risk the market inefficiency driven by investors’ concerns regarding the pace at which Caplyta will be adopted post launch as a differentiated neuropsychiatric product in early 2020, Cantor Fitzgerald analyst Charles Duncan said, ahead of the FDA decision.

See also

See also: